Risk-reducing surgery in women at hereditary risk of gynaecological cancer

Czech version

Authors: Michal Zikán
Authors‘ workplace: Onkogynekologické centrum, Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha, přednosta prof. MUDr. A. Martan, DrSc.
Published in: Ceska Gynekol 2011; 76(3): 216-221

Overview

Objective:
To present up-to-date knowledge concerning risk-reducing surgery in carriers of susceptibility mutations among hereditary breast/ovarian cancer syndrome and Lynch syndrome.

Subject:
Review.

Setting:
Oncogynecological Center, Department of Obstetrics and Gynecology, Charles University in Prague – First Faculty of Medicine and General Faculty Hospital, Prague.

Subject and method:
After having reviewed the now-a-days literature and summarized our experience we present here an overview of risk-reducing strategies in gynecology and a proposal of guidelines to risk-reducing salpingo-oophorectomy and hysterectomy.

Conclusion:
Risk-reducing salpingo-oophorectomy or hysterectomy is the most effective strategy for gynecological cancer prevention in susceptibility gene mutation carriers so far. This type of surgery, however, requires specific indication work-up and techniques different from those standardly used.

Key words:
hereditary breast/ovarian cancer syndrome, hereditary non-polyposis colorectal cancer syndrom, BRCA1, BRCA2, risk-reducing salpino-oophorectomy, risk-reducing hysterectomy.

Sources

1. Aarnio, M., Mecklin, JP., Aaltonen, LA., et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer, 1995, 64(6), p. 430-433.

2. Antoniou, AC., Rookus, M., Andrieu, N., et al. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev, 2009, 18(2), p. 601-610.

3. Beiner, ME., Finch, A., Rosen, B., et al. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol, 2007, 104(1), p. 7-10.

4. Cibula, D., Widschwendter, M., Majek, O., Dusek, L. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update, 2011, 17(1), p. 55-67.

5. Colgan, TJ., Murphy, J., Cole, DE., et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol, 2001, 25(10), p. 1283-1289.

6. de Jong, D., Rosen, BF., Finch, A., et al. Low incidence of ovarian cancer established by prophylactic hysterectomy and BSO in patients with BRCA1 and BRCA2 mutations. 2008; Bangkok.

7. Dunlop, MG., Farrington, SM., Nicholl, I., et al. Population carrier frequency of hMSH2 and hMLH1 mutations. Br J Cancer, 2000, 83(12), p. 1643-1645.

8. Ford, D., Easton, DF., Stratton, M., et al. Genetic heterogenity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet, 1998, 62(3), p. 676-689.

9. Froggatt, NJ., Green, J., Brassett, C., et al. A common MSH2 mutation in English and North American HNPCC families: origin, phenotypic expression, and sex specific differences in colorectal cancer. J Med Genet, 1999, 36(2), p. 97-102.

10. Hogg, R., Friedlander, M. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol, 2004, 22(7), p. 1315-1327.

11. Holmberg, L., Anderson, H. HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomised comparison: trial stopped. Lancet, 2004, 363(9407), p. 453-455.

12. Iodice, S., Barile, M., Rotmensz, N., et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer, 2010, 46(12), p. 2275-2284.

13. Kauff, ND., Domchek, SM., Friebel, TM., et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol, 2008, 26(8), p. 1331-1337.

14. Kauff, ND., Satagopan, JM., Robson, ME., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med, 2002, 346(21), p. 1609-1615.

15. King, MC., Marks, JH., Mandell, JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 2003, 302(5645), p. 643-646.

16. King, MC., Wieand, S., Hale, K., et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA, 2001, 286(18), p. 2251-2256.

17. Lindor, NM., Petersen, GM., Hadley, DW., et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA, 2006, 296(12), p. 1507-1517.

18. Lu, KH., Garber, JE., Cramer, DW., et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol, 2000, 18(14), p. 2728-2732.

19. Madalinska, JB., Hollenstein, J., Bleiker, E., et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol, 2005, 23(28), p. 6890-6898.

20. McLaughlin, JR., Risch, HA., Lubinski, J., et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol, 2007, 8(1), p. 26‑34.

21. Mitrunen, K., Hirvonen, A. Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutat Res, 2003, 544(1), p. 9-41.

22. Modan, B., Hartge, P., Hirsh-Yechezkel, G., et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med, 2001, 345(4), p. 235-240.

23. Narod, SA., Brunet, JS., Ghadirian, P., et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet, 2000, 356(9245), p. 1876-1881.

24. Narod, SA., Dube, MP., Klijn, J., et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst, 2002, 94(23), p. 1773-1779.

25. Narod, SA., Risch, H., Moslehi, R., et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med, 1998, 339(7), p. 424-428.

26. Norquist, BM., Garcia, RL., Allison, KH., et al. The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer, 116(22), p. 5261-5271.

27. Plevová, P., Novotný, J., Petráková, K., et al. Syndrom hereditárního karicnomu prsu a ovarií. Klin Onkol, 2009, 22, Suppl, p. S8-11.

28. Powell, CB., Kenley, E., Chen, LM., et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol, 2005, 23(1), p. 127-132.

29. Rebbeck, TR., Friebel, T., Wagner, T., et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol, 2005, 23(31), p. 7804-7810.

30. Rebbeck, TR., Lynch, HT., Neuhausen, SL., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med, 2002, 346(21), p. 1616-1622.

31. Risch, HA., McLaughlin, JR., Cole, DE., et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet, 2001, 68(3), p. 700-710.

32. Salovaara, R., Loukola, A., Kristo, P., et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol, 2000, 18(11), p. 2193-2200.

33. Schorge, JO., Modesitt, SC., Coleman, RL., et al. SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol, 2010, 119(1), p. 7-17.

34. Stratton, JF., Thompson, D., Bobrow, L., et al. The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study. Am J Hum Genet, 1999, 65(6), p. 1725-1732.

35. Struewing, JP., Hartge, P., Wacholder, S., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med, 1997, 336(20), p. 1401-1408.

36. Swisher, E. Hereditary cancers in obstetrics and gynecology. Clin Obstet Gynecol, 2001, 44(3), p. 450-463.

37. Whittemore, AS., Balise, RR., Pharoah, PD., et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer, 2004, 91(11), p. 1911-1915.

38. Zikán, M. Hereditární syndromy. In Cibula, D., Petruželka, L., ed. Onkogynekologie. Praha: Grada; 2009. p. 614.